Adenium Biotech

Adenium Biotech is a Danish biopharmaceutical company spun out from Novozymes A/S in 2011. Adenium is focused on the development and commercialization of novel antibiotics for the treatment of multi-drug resistant (MDR) bacterial infections.

AA139 is our lead compound, an antimicrobial peptide that is highly effective against MDR Gram-negative bacteria responsible for many of the most serious infections and for which treatment options are becoming increasingly limited. AA139 is currently in pre-clinical development for the treatment of complicated urinary tract infections.
Andreas Segerros


Mobile: +45 53 50 30 38
Email Click here to contact
Adenium Biotech